Through years of scientific and clinical exposure across both human and veterinary medicine, CaniCatiCare Inc. (CCC), a pet precision medicine company, has recognized a persistent distance between the pace of innovation in human healthcare and the way comparable advances reach companion animals. "Human medicine keeps pushing forward with data-driven tests and personalized treatments, while animal healthcare has taken its own route, shaped by different needs and tools," Jaewoo Hong, DVM, founder of CCC and professor at Daegu Catholic University School of Medicine, says. The company aims to serve as a bridge, adapting proven human medical science into tools for veterinary care.
Looking across the broader healthcare landscape, this gap is neither abstract nor theoretical. In human cancer care, precision medicine has evolved to use patient‑specific genetic and molecular information to guide diagnosis and treatment decisions. These insights help clinicians select therapies with a clearer understanding of how a disease may behave. "In veterinary medicine, the science was limited. The problem was the infrastructure around it. We've long understood the biology; what we lacked were tools built specifically for animals," Hong states.
The potential consequences of this translation gap may be felt across the animal health ecosystem. For veterinarians, it can limit the range of clinically informed decisions available within critical timeframes. For pet owners, it can create uncertainty during moments that already carry emotional weight. Meanwhile, for researchers and clinicians alike, it can slow the feedback loop that connects discovery, application, and refinement.
Hong says, "I don't believe these outcomes stem from indifference. They arise from the market structures between two medical fields that evolved in parallel rather than together, which is exactly why cross‑disciplinary innovation deserves greater focus." It's from this recognition of structural separation and the need to close it that CCC's approach to adapting human-grade innovation for animals begins.
CaniCatiCare believes that proven human medical technologies can be thoughtfully adapted for animals without losing rigor or sensitivity to veterinary realities. Rather than attempting to replicate the full complexity of human diagnostics, the company focuses on identifying which elements meaningfully support veterinary decision-making. This perspective is visible in its emphasis on precision tools that aim to balance depth of information with timeliness and accessibility.
A clear example of this approach is reflected in CaniCancer, CCC's flagship offering. CaniCancer represents an effort to identify 23 different cancer mutations covering 70%-80% of the entire canine cancer mutations, supporting clinicians to choose which targeted drug within a day. The service reflects the company's broader commitment to translating human-grade early-stage medical understanding into veterinary-appropriate applications. Importantly, it does so while respecting the veterinarian's role as the primary decision-maker. Hong states, "Our intention has always been to support clinical judgment, not to redefine it. We believe science is at its best when it empowers the professionals delivering care."
By approaching innovation this way, CaniCatiCare highlights the opportunity to elevate animal healthcare standards globally through thoughtful adaptation. Companion animals may share environments and risk factors with humans. When medical knowledge flows responsibly between these domains, it has the potential to improve outcomes while deepening understanding on both sides. This requires sustained attention to where alignment already exists and how it can be responsibly extended.
Overall, CaniCatiCare's perspective contributes to a larger conversation about what modern animal healthcare can become. Its work suggests that progress can also come from recognizing when existing knowledge has not yet reached all the places it can serve. By focusing on translation, collaboration, and scientific continuity, the company frames its mission as part of an ongoing evolution that seeks to narrow longstanding gaps while honoring the distinct contexts of veterinary medicine. In doing so, it invites a more integrated vision of healthcare, where advances in one field can inform and uplift another through clarity and shared purpose.
